Profile data is unavailable for this security.
About the company
Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
- Revenue in GBP (TTM)598.08k
- Net income in GBP-496.59k
- Incorporated2004
- Employees2.00
- LocationProvexis PLC2 Blagrave StreetREADING RG1 1AZUnited KingdomGBR
- Phone+44 175 386 1777
- Websitehttps://www.provexis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genflow Biosciences PLC | 0.00 | -1.63m | 7.52m | 5.00 | -- | 8.66 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.33m | 8.25m | 10.00 | -- | 2.33 | -- | -- | -0.0352 | -0.0352 | 0.00 | 0.0428 | 0.00 | -- | -- | 0.00 | -50.56 | -- | -57.49 | -- | -- | -- | -- | -- | -- | -- | 0.1267 | -- | -- | -- | -6.71 | -- | -- | -- |
| ImmuPharma PLC | 69.96k | -2.99m | 9.33m | 13.00 | -- | 4.30 | -- | 133.34 | -0.0092 | -0.0092 | 0.0002 | 0.0052 | 0.0227 | -- | 0.1706 | 5,381.54 | -97.05 | -89.69 | -159.35 | -106.57 | -- | -- | -4,275.31 | -7,958.69 | -- | -2.40 | 0.00 | -- | -100.00 | -- | 53.42 | -- | 32.98 | -- |
| Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 9.52m | 91.00 | -- | 1.02 | -- | 1.05 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
| Proteome Sciences plc | 5.03m | -2.44m | 10.33m | 35.00 | -- | -- | -- | 2.05 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Kanabo Group PLC | 895.00k | -7.99m | 10.75m | 20.00 | -- | 1.43 | -- | 12.01 | -0.0137 | -0.0137 | 0.0017 | 0.0119 | 0.0785 | 11.11 | 28.41 | -- | -70.12 | -75.83 | -77.61 | -83.33 | 14.97 | -- | -893.30 | -1,267.35 | 4.96 | -10.43 | 0.035 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 12.15m | 2.00 | -- | -- | -- | 82.87 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Provexis plc | 598.08k | -496.59k | 12.90m | 2.00 | -- | 12.86 | -- | 21.57 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 13.62m | 82.00 | -- | 7.21 | -- | 2.55 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Shield Therapeutics PLC | 13.09m | -33.29m | 13.69m | 73.00 | -- | 0.9104 | -- | 1.05 | -0.0458 | -0.0458 | 0.0181 | 0.0192 | 0.347 | 3.65 | 1.31 | 179,246.60 | -88.29 | -56.68 | -136.30 | -67.44 | 30.78 | 52.20 | -254.44 | -365.89 | 2.04 | -30.01 | 0.5739 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
| Genincode PLC | 1.72m | -6.73m | 14.60m | 28.00 | -- | 1.66 | -- | 8.51 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Synairgen plc | 0.00 | -9.99m | 14.68m | 30.00 | -- | 0.9196 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| LungLife AI Inc | 36.21k | -4.26m | 15.60m | 15.00 | -- | 0.8548 | -- | 430.81 | -0.1672 | -0.1672 | 0.0014 | 0.2444 | 0.0038 | -- | 0.2831 | 2,413.93 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Destiny Pharma PLC | 0.00 | -5.66m | 15.73m | 19.00 | -- | 1.71 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | 0.00 | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.02 | -- | 35.39 | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.75m | 3.00 | -- | 1.76 | -- | 25.76 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| Oncimmune Holdings PLC | 1.15m | -6.15m | 18.46m | 56.00 | -- | 28.10 | -- | 16.03 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to Provexis PLC's reporting currency: UK Pound GBX
12.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 125.49m | 5.55% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Apr 2024 | 39.10m | 1.73% |
| IG Markets Ltd.as of 01 Apr 2024 | 20.31m | 0.90% |
| Evelyn Partners Investment Management LLPas of 01 Apr 2024 | 15.92m | 0.70% |
| KW Investment Management Ltd.as of 01 Apr 2024 | 14.20m | 0.63% |
| HSBC Bank Plc (Market-Maker)as of 01 Apr 2024 | 13.63m | 0.60% |
| Quilter Cheviot Ltd.as of 01 Apr 2024 | 12.66m | 0.56% |
| Investec Wealth & Investment Ltd.as of 01 Apr 2024 | 11.74m | 0.52% |
| abrdn Investment Management Ltd.as of 01 Apr 2024 | 10.79m | 0.48% |
| Morgan Stanley Securities Ltd. (Market-Maker)as of 01 Apr 2024 | 8.50m | 0.38% |
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
